Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 413 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Muscular Dystrophies Clear all

Conditions: Duchenne Muscular Dystrophy
Interventions: scAAV9.U7.ACCA; Biological
Lead sponsor: Megan Waldrop; Other
Eligibility: 6 Months to 13 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Muscular Dystrophy, Duchenne
Interventions: SRP-5051; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Hartford, Connecticut • Gulf Breeze, Florida • Atlanta, Georgia + 4 more

Conditions: Genetic Disorder
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: LGMD2I
Interventions: BBP-418; Drug
Lead sponsor: ML Bio Solutions, Inc.; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Duchenne Muscular Dystrophy
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older
U.S. locations: 42
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more

Conditions: Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Spinal Cord Injuries, Stroke, Lacunar, Stroke Brainstem, Cervical Spinal Cord Injury, Spinal Muscular Atrophy, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions: Motor Neuroprosthesis (MNP); Device
Lead sponsor: Synchron Medical, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Buffalo, New York • New York, New York • Pittsburgh, Pennsylvania

Conditions: Muscular Dystrophies, Limb-Girdle
Interventions: SRP-9005, Corticosteroid; Biological · Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Limb-Girdle Muscular Dystrophy, Type 2E
Interventions: SRP-9003; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 15 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Muscular Dystrophies
Interventions: Albuterol, Oxandrolone; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: WVE-210201, Placebo; Drug
Lead sponsor: Wave Life Sciences USA, Inc.; Industry
Eligibility: 5 Years to 18 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neuromuscular; Disorder, Hereditary, Duchenne/Becker Muscular Dystrophy, Limb-girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Week to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Muscular Dystrophy
Interventions: Tadalafil 20 MG, beetroot juice extract; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myotonic Dystrophy 2
Interventions: Exercise; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 2 Years to 5 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Gulf Breeze, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, PLACEBO; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 19 more

Conditions: Constipation, DMD
Interventions: SmartPill ingestion; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Merosin Deficient Congenital Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Prothelia, Inc.; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Duchenne Muscular Dystrophy
Interventions: Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC); Biological
Lead sponsor: MED Institute Inc.; Industry
Eligibility: 5 Years to 10 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Dallas, Texas • Flower Mound, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: Exercising, Optical and Magnetic Resonance Imaging and Spectroscopy; Other · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 10 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Duchenne Muscular Dystrophy
Interventions: AVI-4658 (Eteplirsen), Placebo; Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 7 Years to 13 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Interventions: Neurosleeve; Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 4 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Wilmington, Delaware • Philadelphia, Pennsylvania

Conditions: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions: BBP-418 (ribitol), Placebo; Drug · Other
Lead sponsor: ML Bio Solutions, Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Little Rock, Arkansas • Irvine, California • Aurora, Colorado + 9 more

Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 62 Years · Male only
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Gainesville, Florida • Portland, Oregon • Philadelphia, Pennsylvania

Search by objective public record fields.

AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Study of BBP-418 in Patients With LGMD2I

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

Molecular Analysis of Patients With Neuromuscular Disease

The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy

Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Constipation and Gut Transit in DMD Patients

Retrospective Natural History Study of Infants and Toddlers With LAMA2-CMD

Study of UC-MSC in DMD Patients

Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy